Former Ignyta executive Zachary Hornby wasn't wowed by immuno-oncology pitches when looking for his next cancer drug development company, but was intrigued by ecDNA research at UCSD, which also could generate a tumor agnostic approach.

Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for chikungunya and advance its oncology franchise.

The Swiss major has new data on its SMA gene therapy which has been found not to be the cause of the death of a six-month-old patient earlier this year.

PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.

Bayer is boosting its AI drive by investing in One Drop’s digital platform and hopes to advance outcomes in oncology, heart disease and women’s health with data-driven solutions.

Emerging Company Profile: CHF16m for Swiss firm that engineers liposomes to capture toxins and protect the organs of patients with acute liver failure.

Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for chikungunya and advance its oncology franchise.

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Sanofi's latest digital health move will see it collaborating with Happify Health on a digital therapeutic for patients with multiple sclerosis, a therapeutic area it knows well.

Bayer is boosting its AI drive by investing in One Drop’s digital platform and hopes to advance outcomes in oncology, heart disease and women’s health with data-driven solutions.

Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.

Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.

The US firm has withdrawn its submission to get EU approval for Xyndari. After being turned down by the CHMP, Emmaus may try the decentralized approval procedure instead.

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

With a broader ecosystem of prescription influencers emerging rapidly in India, pharma needs to engage with these groups extensively, a conference in Mumbai hears.

PPF has bought a big stake in the UK-based T-cell specialist, one of many firms backed by investor Neil Woodford which have suffered stock slides in the past few months.

Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.

Novartis looks to differentiate ofatumumab from Roche's entrenched MS blockbuster Ocrevus, stressing that patients can inject the therapy at home.

The US firm has withdrawn its submission to get EU approval for Xyndari. After being turned down by the CHMP, Emmaus may try the decentralized approval procedure instead.

China’s massive centralized "4+7" drug procurement scheme is now being rolled out nationwide, involving some of the largest provincial markets and huge product volumes.

More than two years after EU approval, BioMarin and the National Health Service have agreed pricing for the ultra-rare disease therapy, Brineura, allowing it to be publicly funded while further clinical data are collected as part of a managed access agreement.

The future looks rosy after a slow start for antibody-drug conjugates. But what are the best tactics to capture a slice of the growing opportunity?

Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.

AstraZeneca’s head of R&D spoke to Scrip about the outstanding results for dapagliflozin in heart failure regardless of diabetes status.